Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Argon plasma coagulation treatment of anal high-grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2-year prospective pilot study.

de Pokomandy A, Rouleau D, Lalonde R, Beauvais C, de Castro C, Coutlée F; Human Immunodeficiency and Papilloma Virus Research Group (HIPVIRG) Study Group.

HIV Med. 2017 Aug 23. doi: 10.1111/hiv.12544. [Epub ahead of print]

PMID:
28833949
2.

Tolerability is more important than simplicity for treatment durability.

Trottier B, Machouf N, Huchet E, Lavoie S, Vezina S, Boissonnault M, Charest L, Munoz M, Legault D, Longpré D, Thomas R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19765. doi: 10.7448/IAS.17.4.19765. eCollection 2014.

3.

Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy.

Trottier B, Machouf N, Thomas R, Gallant S, Longpré D, Vézina S, Boissonnault M, Lavoie S, Legault D, Dion H, Nguyen VK.

HIV Clin Trials. 2012 Nov-Dec;13(6):335-42. doi: 10.1310/hct1306-335.

PMID:
23195671
4.

Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.

Kamya P, Tallon B, Melendez-Pena C, Parsons MS, Migueles SA, Connors M, Miconiatis S, Song R, Boulet S, Bruneau J, Tremblay CL, Bernard NF; investigators of the Canadian Cohort of HIV Infected Slow Progressors.

Clin Immunol. 2012 Jun;143(3):246-55. doi: 10.1016/j.clim.2012.01.001. Epub 2012 Jan 15.

PMID:
22445844
5.

Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec.

Brenner BG, Roger M, Stephens D, Moisi D, Hardy I, Weinberg J, Turgel R, Charest H, Koopman J, Wainberg MA; Montreal PHI Cohort Study Group.

J Infect Dis. 2011 Oct 1;204(7):1115-9. doi: 10.1093/infdis/jir468.

6.

Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles.

Peretz Y, Marra O, Thomas R, Legault D, Côté P, Boulassel MR, Rouleau D, Routy JP, Sékaly RP, Tsoukas CM, Tremblay C, Bernard NF.

Viral Immunol. 2011 Jun;24(3):189-98. doi: 10.1089/vim.2010.0117.

PMID:
21668360
7.

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors.

J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6.

8.

Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men.

Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Allaire G, Hadjeres R, Franco EL, Coutlée F; HIPVIRG Study Group.

AIDS. 2010 Sep 24;24(15):2355-63. doi: 10.1097/QAD.0b013e32833db9ea.

PMID:
20706109
9.

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.

Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA; Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.

Am J Cardiol. 2009 Sep 15;104(6):798-804. doi: 10.1016/j.amjcard.2009.05.019. Epub 2009 Jul 23.

PMID:
19733714
10.

Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study.

de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EL, Coutlée F; HIPVIRG Study Group.

J Infect Dis. 2009 Apr 1;199(7):965-73. doi: 10.1086/597207.

PMID:
19239366
11.

HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease.

Fontaine J, Coutlée F, Tremblay C, Routy JP, Poudrier J, Roger M; Montreal Primary HIV Infection and Long-Term Nonprogressor Study Groups.

J Infect Dis. 2009 Apr 1;199(7):1007-18. doi: 10.1086/597278.

PMID:
19231994
12.

Transmission networks of drug resistance acquired in primary/early stage HIV infection.

Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA; Montreal PHI Cohort and HIV Prevention Study Groups.

AIDS. 2008 Nov 30;22(18):2509-15. doi: 10.1097/QAD.0b013e3283121c90.

13.

Genotyping of human papillomavirus DNA in anal biopsies and anal swabs collected from HIV-seropositive men with anal dysplasia.

Gohy L, Gorska I, Rouleau D, Ghattas G, Pokomandy Ad, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R, Kornegay JR, Franco E; HIPVIRG Study Group, Coutlée F.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):32-9. doi: 10.1097/QAI.0b013e318183a905.

PMID:
18667921
14.

The Public Population Project in Genomics (P3G): a proof of concept?

Knoppers BM, Fortier I, Legault D, Burton P.

Eur J Hum Genet. 2008 Jun;16(6):664-5. doi: 10.1038/ejhg.2008.55. Epub 2008 Apr 2. No abstract available.

15.

Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome.

Legault D, McDermott J, Crous-Tsanaclis AM, Boire G.

J Rheumatol. 2008 Jan;35(1):169-71.

PMID:
18176990
16.

KATP channels depress force by reducing action potential amplitude in mouse EDL and soleus muscle.

Gong B, Legault D, Miki T, Seino S, Renaud JM.

Am J Physiol Cell Physiol. 2003 Dec;285(6):C1464-74. Epub 2003 Aug 13.

PMID:
12917105
17.

ICAM-1 isoforms: specific activity and sensitivity to cleavage by leukocyte elastase and cathepsin G.

Robledo O, Papaioannou A, Ochietti B, Beauchemin C, Legault D, Cantin A, King PD, Daniel C, Alakhov VY, Potworowski EF, St-Pierre Y.

Eur J Immunol. 2003 May;33(5):1351-60.

18.

Modulation of integrin-mediated intercellular adhesion during the interaction of thymocytes with stromal cells expressing VLA-4 and LFA-1 ligands.

St-Pierre Y, Hugo P, Legault D, Tremblay P, Potworowski EF.

Eur J Immunol. 1996 Sep;26(9):2050-5.

PMID:
8814245
19.

Long-term intraperitoneal deferoxamine for hemochromatosis.

Swartz RD, Legault DJ.

Am J Med. 1996 Mar;100(3):308-12.

PMID:
8629676
20.

Supplemental Content

Loading ...
Support Center